Related references
Note: Only part of the references are listed.Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children The SCOUT-CAP Randomized Clinical Trial
Derek J. Williams et al.
JAMA PEDIATRICS (2022)
Antibiotic Development Incentives That Reflect Societal Value of Antibiotics
Helen W. Boucher et al.
CLINICAL INFECTIOUS DISEASES (2021)
Patients' Experiences With Staphylococcus aureus and Gram-negative Bacterial Bloodstream Infections: A Qualitative Descriptive Study and Concept Elicitation Phase To Inform Measurement of Patient-reported Quality of Life
Heather A. King et al.
CLINICAL INFECTIOUS DISEASES (2021)
Antibacterial Resistance Leadership Group 2.0: Back to Business
Henry F. Chambers et al.
CLINICAL INFECTIOUS DISEASES (2021)
The Emperor's New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE)
Thomas P. Lodise et al.
CLINICAL INFECTIOUS DISEASES (2020)
Antibiotic development - economic, regulatory and societal challenges
Christine Ardal et al.
NATURE REVIEWS MICROBIOLOGY (2020)
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study
David van Duin et al.
LANCET INFECTIOUS DISEASES (2020)
Good Studies Evaluate the Disease While Great Studies Evaluate the Patient: Development and Application of a Desirability of Outcome Ranking Endpoint for Staphylococcus aureus Bloodstream Infection
Sarah B. Doernberg et al.
CLINICAL INFECTIOUS DISEASES (2019)
Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial
Keith S. Kaye et al.
CLINICAL INFECTIOUS DISEASES (2019)
Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
George H. Talbot et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial
Simon Portsmouth et al.
LANCET INFECTIOUS DISEASES (2018)
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae
David van Duin et al.
CLINICAL INFECTIOUS DISEASES (2018)
Developing Outcomes Assessments as Endpoints for Registrational Clinical Trials of Antibacterial Drugs: 2015 Update From the Biomarkers Consortium of the Foundation for the National Institutes of Health
George H. Talbot et al.
CLINICAL INFECTIOUS DISEASES (2016)
Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team
Charles Knirsch et al.
CLINICAL INFECTIOUS DISEASES (2016)
Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step Toward Pragmatism in Benefit:Risk Evaluation
Scott R. Evans et al.
STATISTICS IN BIOPHARMACEUTICAL RESEARCH (2016)
Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR)
Scott R. Evans et al.
CLINICAL INFECTIOUS DISEASES (2015)
Intravenous Doripenem at 500 Milligrams versus Levofloxacin at 250 Milligrams, with an Option To Switch to Oral Therapy, for Treatment of Complicated Lower Urinary Tract Infection and Pyelonephritis
K. G. Naber et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Share Paper
